巴黎生物技术新星Aqemia近日宣布，成功获得3000万欧元的A轮融资追加资金，使得其A轮融资总额达到6000万欧元。本轮融资由知名投资机构Wendel Growth领投，Eurazeo、Bpifrance和Elaia等现有投资者积极参与。Aqemia专注于利用先进的生成式人工智能技术革新药物发现与设计领域，致力于打造更高效的药物研发流程。
Aqemia的人工智能平台声称能够显著加速分子的发现与设计，为对抗各种疾病提供潜在的新药候选分子。这家初创公司的创新方法为传统药物研发带来了革命性的变化，有望缩短研发周期，降低研发成本，从而更快地将新药推向市场。
此次融资的注入，不仅彰显了投资者对Aqemia技术潜力和市场前景的信心，也将助力公司进一步加强研发能力，扩大团队规模，并加速其技术在全球医药行业的应用和推广。Aqemia的创新模式为生物科技与人工智能的交叉融合树立了新的标杆，预示着未来医药研发领域将有更多AI驱动的突破。
英语如下：
News Title: “AI制药先锋 Aqemia Secures €60 Million Funding, Boosting Drug Discovery Innovation”
Keywords: AI drug discovery, Aqemia funding, Paris biotech
News Content:
Title: Aqemia Closes €30 Million Series A Extension, Accelerating AI-Powered Drug Discovery
Paris-based biotech startup Aqemia has announced a €30 million Series A extension, bringing its total funding to €60 million. The round was led by prominent investor Wendel Growth, with strong participation from existing backers Eurazeo, Bpifrance, and Elaia. Aqemia focuses on revolutionizing drug discovery and design using advanced generative AI technologies to streamline the pharmaceutical development process.
The company’s AI platform claims to significantly speed up molecule discovery and design, offering potential new drug candidates for combating various diseases. Aqemia’s innovative approach disrupts traditional drug R&D, potentially reducing development timelines and costs, thereby expediting new drugs’ journey to market.
This funding round not only underscores investors’ confidence in Aqemia’s technological potential and market prospects but also empowers the company to enhance its R&D capabilities, expand its team, and accelerate the global adoption and application of its technology within the pharmaceutical industry. Aqemia sets a new benchmark for the convergence of biotech and AI, foreshadowing more AI-driven breakthroughs in future医药 research and development.
【来源】https://sifted.eu/articles/aqemia-60m-series-a
Views: 1